In financial accounting, a balance sheet is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity.

Argenica Therapeutics Limited Balance Sheet Statement - Assets

As of 30 Jun 2022, The total current assets of Argenica Therapeutics Limited (ASX:AGN) was around $9,042,400 which consisted of $8,914,457 of Cash, no Inventory and $72,080 of Net receivables. Current assets represent all the assets of a company that are expected to be conveniently sold, consumed, used, or exhausted through standard business operations within one year.

All amounts in AUD

Current assets
Total assets

The latest balance sheet of Argenica Therapeutics Limited also showed no Property Plant Equipment and no Good will. Also there were $1,000 of Intangible assets and no Other assets. The total assets including current and Intangibles/Deferred Long Term Asset Charges were $9,043,400.

Argenica Therapeutics Limited Balance Sheet Statement - Liabilities

AGN's latest annual results shows the balance sheet has $671,825 of Accounts Payable. Also there were no Short/Long term debt, no Long term debt, $19,059 of Other Current liabilities and $735,909 of Total Current Liabilities. Current liabilities are a company's short-term financial obligations that are due within one year or within a normal operating cycle.

Account payable
Current liabilities
Total liabilities

As per the 30 Jun 2022's annual report of Argenica Therapeutics Limited, the total liabilities were $735,909.

AGN Balance Sheet Statement - Stock Holder Equity

Stockholders' equity, also referred to as shareholders' equity, is the remaining amount of assets available to shareholders after all liabilities have been paid. It is calculated either as a firm's total assets less its total liabilities or alternatively as the sum of share capital and retained earnings less treasury shares. Stockholders' equity might include common stock, paid-in capital, retained earnings and treasury stock.

The latest Balance sheet of Argenica Therapeutics Limited showed the total stock holder equity was $8,307,491 which consisted of $13,065,033 of Common stocks, $-5,503,656 of Retained earnings and $746,114 of Other stock holder equity.

AGN Balance Sheet Statement History

Following table shows the history of balance sheet for Argenica Therapeutics Limited (AGN).

30 Jun 202230 Jun 202130 Jun 2020
Net Receivables72.08k78.08k34.58k
Total Current Assets9.04M7.27M376.66k
Property Plant Equipment---
Good Will---
Intangible Assets1k1k1k
Other Assets---
Deferred Long Term Asset Charges---
Total Assets9.04M7.27M377.66k
Accounts Payable671.83k373.58k353.26k
Short/Long Term Debt---
Other Current Liabilities19.06k14.42k-
Long Term Debt---
Other Liabilities---
Total Current Liabilities735.91k425.72k359.26k
Total Liabilities735.91k425.72k359.26k
Common Stock13.07M8.05M401.8k
Retained Earnings-5.5M-1.41M-383.4k
Treasury Stock746.11k208.64k-
Other Stockholder Equity746.11k208.64k-
Total Stockholder Equity8.31M6.85M18.4k
Net Tangible Assets8.31M6.85M17.4k

Argenica Therapeutics Limited (ASX:AGN) Balance Sheet Statement FAQ

1. How much Cash Argenica Therapeutics Limited has on their balance sheet?

As of 30 Jun 2022, Argenica Therapeutics Limited (ASX:AGN) has $8,914,457 of Cash.

2. What's the long term debt of Argenica Therapeutics Limited?

As per the latest Balance sheet of Argenica Therapeutics Limited (ASX:AGN), it has no Long term debt.

3. How much share holder equity does Argenica Therapeutics Limited has?

The Argenica Therapeutics Limited (ASX:AGN)'s balance sheet shows that it has $8,307,491 of Total stock holder equity.